Cardinal Health Inc (CAH)

Cardinal Health Inc (CAH-N) is viewed positively by analysts with a target price that reflects confidence in its future performance. One expert particularly highlights the strategic acquisition of a urology company, suggesting it strengthens Cardinal's position in the market. Another analyst points to the company's role as one of the three major distributors in healthcare, emphasizing the favorable demographics of an aging population and increasing prescriptions as significant growth drivers. Despite recent market fluctuations following the acquisition of Solaris, they believe that Cardinal is currently undervalued, trading at 16x forward PE aligned with a 13% EPS growth, which signals a promising investment opportunity. The stock's dividend yield of 1.35% adds to its appeal for investors looking for stability in earnings growth amidst market uncertainties.